NEW YORK (GenomeWeb) – VolitionRx today announced that the University of Bonn in Germany will begin a clinical study to assess VolitionRx's Nucleosomics platform for the diagnosis of lung cancer through a non-invasive blood test.

The study will be conducted as a separate trial in conjunction with the firm's larger 4,000-subject prospective study at University Hospital Bonn, evaluating NuQ assays in the 20 most prevalent cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.